A drug called zanzalintinib for children and teens with solid tumors that came back
Official title: Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This study is testing how safe a drug called zanzalintinib is for young people with cancer.
Read our full plain-language summary
What the trial team says
The primary purpose of this study is to determine the pediatric maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and to evaluate the safety and tolerability of zanzalintinib.
Key facts
- Registry number
- NCT07773454
- Stage of testing
- Phase 1
- Conditions studied
- Cancer, Pediatric Cancer
Where it is running
No locations are listed for this trial. The trial's own page may have more.
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.